Italia markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,17000,0000 (0,00%)
Alla chiusura: 04:00PM EDT
1,1400 -0,03 (-2,56%)
Dopo ore: 07:17PM EDT

Citius Pharmaceuticals, Inc.

11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://www.citiuspharma.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno21

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Leonard L. MazurCo-Founder, CEO, Chairman & Sec.570kN/D1945
Mr. Myron Z. HolubiakCo-Founder & Exec. Vice Chairman620kN/D1947
Mr. Jaime BartushakChief Bus. Officer, CFO & Chief Accounting Officer527,97kN/D1968
Dr. Myron S. Czuczman M.D.Exec. VP & Chief Medical Officer550,92kN/D1960
Mr. Gary F. TalaricoExec. VP of OperationsN/DN/D1955
Ms. Ilanit AllenVP of Investor Relations & Corp. CommunicationsN/DN/DN/D
Dr. Alan Lader Ph.D.Sr. VP and Head of Clinical Operations & Quality AssuranceN/DN/DN/D
Mr. Dhananjay G. WadekarSr. VP of Bus. StrategyN/DN/D1954
Mr. Kelly Creighton Ph.D.Exec. VP of Chemistry, Manufacturing & ControlsN/DN/DN/D
Mr. Nikolas BurlewExec. VP of Quality AssuranceN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Citius Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.